<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>422-POLYMYXIN-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POLYMYXIN B" rxcui="8536">
<ATC code="A07AA05" />
<ATC code="J01XB02" />
<ATC code="S01AA18" />
<ATC code="S02AA11" />
<ATC code="S03AA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="AMINOGLYCOSIDES" code="J01GB-001" /></DRUG2>
<DESCRIPTION>Addition of the nephrotoxic effects

.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together cannot be avoided, strict monitoring with an indisputable bacteriological justification</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>422-POLYMYXIN-B.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POLYMYXIN B" rxcui="8536">
<ATC code="A07AA05" />
<ATC code="J01XB02" />
<ATC code="S01AA18" />
<ATC code="S02AA11" />
<ATC code="S03AA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="CURARES" code="M03A-001" /></DRUG2>
<DESCRIPTION>Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitor the degree of curarization at the end of anesthesia</COMMENT>
</INTERACTION>
</INTERACTIONS>
